2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-145052
    HBV-IN-9
    		Inhibitor
    HBV-IN-9 is a potent HBsAg (HBV Surface antigen) inhibitor (IC50=10 nM) and HBV DNA production inhibitor (IC50=0.15 nM in HepG2.2.15 cells). From patent WO2018001952A1, example 20.
    HBV-IN-9
  • HY-149815
    HBV-IN-33
    		Inhibitor
    HBV-IN-33 (C-49), a HBV inhibitor, notably suppresses HBV replication in HepAD38, HepG2-HBV1.3 and HepG2-NTCP cells.
    HBV-IN-33
  • HY-W654247
    Lamivudine-13C,d2
    Lamivudine-13C,d2 is the deuterium labeled and 13C-labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS.
    Lamivudine-<sup>13</sup>C,d<sub>2</sub>
  • HY-168045
    HBV-IN-48
    		Inhibitor
    HBV-IN-48 is an HBV inhibitor. HBV-IN-48 has antiviral activity against HBV in HepDE19 cells, with an EC50 value of 0.005 μM. HBV-IN-48 can reduce serum HBV DNA levels in mouse models of HBV infection.
    HBV-IN-48
  • HY-145871
    BA38017
    		Inhibitor
    BA38017 is a potent HBV core protein assembly modulator. BA38017 inhibits HBV replication with an EC50 of 0.20 μM.
    BA38017
  • HY-163124
    HBV-IN-43
    HBV-IN-43 (compound 5832) is a potent inhibitor of HBV.
    HBV-IN-43
  • HY-147266A
    Elebsiran
    		Inhibitor
    Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections.
    Elebsiran
  • HY-126033
    Sophoranol
    		Inhibitor
    Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratory syncytial virus (RSV) with an IC50 of 10.4 μg/mL.
    Sophoranol
  • HY-P4049
    HBV Seq1 aa:63-71
    HBV Seq1 aa:63-71 is the fragment of hepatitis B virus (HBV).
    HBV Seq1 aa:63-71
  • HY-177654
    Ozisiran
    		Inhibitor
    Ozisiran, a siRNA, is a hepatitis B virus (HBV) RNA transcript reducer with antiviral activity.
    Ozisiran
  • HY-14404
    MK-1220
    		Inhibitor
    MK-1220 is a covalently reversible inhibitor of the hepatitis C virus (HCV) NS3/4A protease (NS3/4A protease) with a Ki of 0.02 nM. MK-1220 in cell models simulating viral replication exhibits EC50s of 4 (with 10% fetal bovine serum) and 11 nM (50% normal human serum). MK-1220 can be used for the study of chronic hepatitis C virus infection.
    MK-1220
  • HY-N6939R
    Pseudolaric Acid B (Standard)
    		Inhibitor
    Pseudolaric Acid B (Standard) is the analytical standard of Pseudolaric Acid B. This product is intended for research and analytical applications. Pseudolaric Acid B is an orally active diterpene acid. Pseudolaric Acid B has anti-fungal, anti-fertility, anti-angiogenesis and anticancer activity, and can induce tumor cell apoptosis and autophagy. In addition, Pseudolaric Acid B can inhibit the secretion of hepatitis B virus (HBV) and has immunosuppressive effect, selectively inhibiting the proliferation of T lymphocytes and the production of IL-2.
    Pseudolaric Acid B (Standard)
  • HY-Y0073R
    4-Hydroxyacetophenone (Standard)
    		Inhibitor
    4-Hydroxyacetophenone (Standard) is the analytical standard of 4-Hydroxyacetophenone. This product is intended for research and analytical applications. 4-Hydroxyacetophenone (P-hydroxyacetophenone) is a major hepatoprotective and choleretic compound found in Artemisia and Illicium plants, exhibiting antiviral and anti-inflammatory effects against hepatitis B virus. Additionally, 4-Hydroxyacetophenone inhibits cancer cell adhesion, invasion, and migration by remodeling actin. 4-Hydroxyacetophenone holds promise for research in the fields of inflammatory diseases and cancer.
    4-Hydroxyacetophenone (Standard)
  • HY-156272
    HBV-IN-41
    		Inhibitor
    HBV-IN-41 (compound 45) is a potent and orally active Hepatitis B Virus (HBV) inhibitor, with an EC50 of 0.027μM.
    HBV-IN-41
  • HY-13623S1
    Entecavir-13C2,15N
    		Inhibitor
    Entecavir-13C2,15N (BMS200475-13C2,15N; SQ34676-13C2,15N) is a 13C- and 15N-labeled Entecavir (HY-13623). Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.
    Entecavir-<sup>13</sup>C<sub>2</sub>,<sup>15</sup>N
  • HY-109969
    Z060228
    		Inhibitor
    Z060228 is a capsid-targeting anti-HBV agent that inhibits HBV DNA replication in the supernatant of the HepG2.2.15 cell.
    Z060228
  • HY-145638X
    GalNAc unconjugated/naked Xalnesiran
    		Inhibitor
    GalNAc unconjugated/naked Xalnesiran is a non-GalNAc-conjugated Xalnesiran (HY-145638). Xalnesiran is siRNA for the study of chronic hepatitis B (HBV).
    GalNAc unconjugated/naked Xalnesiran
  • HY-127122
    Valtorcitabine dihydrochloride
    		Inhibitor
    Valtorcitabine dihydrochloride is a prodrug of L-deoxycytidine and also is an HBV inhibitor.
    Valtorcitabine dihydrochloride
  • HY-N8168
    LPRP-Et-97543
    		Inhibitor
    LPRP-Et-97543 is a potent anti-HBV agent. LPRP-Et-97543 reduces Core, S, and preS but not X promoter activities. LPRP-Et-97543 can be used for acute and chronic HBV infections research.
    LPRP-Et-97543
  • HY-106235
    LB80317
    		Inhibitor
    LB80317 is an active metabolite of LB80380 and suppresses the DNA synthesis of HBV with an EC50 of 0.5 μM. LB80317 has antiviral effect and has the potential for chronic hepatitis B treatment.
    LB80317
Cat. No. Product Name / Synonyms Application Reactivity